BPMX BioPharmX Corporation. Common

0.29
+0.01  (3%)
Previous Close 0.28
Open 0.28
Price To book 27.45
Market Cap 23104252
Shares 79,669,835
Volume 1,931,887
Short Ratio 3.61
Av. Daily Volume 1,013,927

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated in 2017
BPX-03
Moderate to severe periodic breast pain associated with FBC (fibrocystic breast condition) and cyclic mastalgia
Phase 2b data released May 3, 2017 - primary endpoint met, secondary missed.
BPX-01
Acne

Latest News

  1. BioPharmX to Present at Re-entering Antibacterial Discovery and Development Summit 2017
  2. BioPharmX Collaborates with Wellman Center for Photomedicine to Develop Pioneering, Cost-Effective Technique to Visualize Drug Delivery
  3. ETFs with exposure to BioPharmX Corp. : October 10, 2017
  4. Is BioPharmX Corporation (BPMX) Still A Cheap Healthcare Stock?
  5. ETFs with exposure to BioPharmX Corp. : September 26, 2017
  6. Earnings Review and Free Research Report: Can-Fite’s Revenue Increased 25%
  7. BioPharmX Corp. :BPMX-US: Earnings Analysis: Q2, 2018 By the Numbers : September 14, 2017
  8. BioPharmX Reports Second Quarter 2018 Financial Results
  9. BioPharmX Announces Preliminary Data from Rosacea Feasibility Study
  10. BioPharmX to Present at Rodman & Renshaw 19th Annual Global Investment Conference
  11. Summer AAD Panel to Discuss BPX-01 for Acne and Rosacea
  12. BioPharmX To Present Phase 2b Clinical Trial Data at National DEF Essential Resource Meeting 2017
  13. ETFs with exposure to BioPharmX Corp. : July 12, 2017
  14. Corporate News Blog - Repligen Corp. and Spectrum Merge to Form Leader in Filtration for Bioprocessing Industry
  15. BioPharmX to Present Phase 2b Clinical Trial Acne Data at Alabama Dermatology Society Summer Symposium
  16. ETFs with exposure to BioPharmX Corp. : June 19, 2017
  17. BioPharmX Corp. :BPMX-US: Earnings Analysis: Q1, 2018 By the Numbers : June 16, 2017
  18. BioPharmX Invited to Present at World Preclinical Congress
  19. BioPharmX Reports First Quarter 2018 Financial Results